A patient with ige having treatment under immuno suppression vaccine and motelokast facing itching and facing problems with water get itching other
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Based on the clinical information retrieved from authoritative dermatology and internal medicine textbooks, here is a comprehensive clinical analysis of this patient's situation:
Clinical Overview: IgE-Mediated Allergy + Immunotherapy + Montelukast + Water-Triggered Itching
Understanding the Patient's Condition
This patient appears to have IgE-mediated allergic disease being managed with:
- Allergen immunotherapy (allergy vaccine/desensitization)
- Montelukast (leukotriene receptor antagonist)
- Immunosuppression
They are experiencing pruritus (itching) triggered by water contact — this points to either aquagenic urticaria or aquagenic pruritus.
1. Aquagenic Urticaria vs. Aquagenic Pruritus
| Feature | Aquagenic Urticaria | Aquagenic Pruritus |
|---|---|---|
| Trigger | Water of any temperature | Water of any temperature |
| Skin finding | Wheals/hives with flare | No wheals — itching/prickling only |
| Association | Cholinergic urticaria overlap | Systemic disease (e.g., polycythemia vera), dry skin, dermographism |
| Treatment response | Antihistamines, montelukast | Antihistamines, UV therapy |
— Dermatology 2-Volume Set 5e; Andrews' Diseases of the Skin
2. Role of Montelukast in This Scenario
Montelukast (a CysLT1 receptor antagonist) is used in urticaria management as an add-on agent when H1 antihistamines alone are insufficient:
"The addition of an H2 antagonist and a CysLT receptor antagonist, such as montelukast 10 mg daily, may add benefit when H1 antihistamines are inadequate." — Harrison's Principles of Internal Medicine 22E, p. 2852
Montelukast is particularly useful in:
- Aspirin/NSAID-sensitive chronic urticaria (leukotrienes are central mediators)
- Physical/inducible urticarias (aquagenic, pressure-induced)
- Atopic dermatitis
3. Why Itching Persists Despite Current Treatment
Several possible reasons:
a) Incomplete mast cell suppression
IgE is bound to mast cells. During allergen immunotherapy, mast cell reactivity can temporarily increase early in the desensitization course, potentially worsening urticaria or pruritus transiently.
b) Aquagenic pruritus as a distinct entity
If the itching occurs with water contact without wheals, this is aquagenic pruritus — a condition where neither antihistamines nor montelukast may fully control symptoms. Contributing causes include:
- Polycythemia vera (must be ruled out)
- Dry skin / xerosis
- Mast cell disorders
c) Immunosuppression effect
Some immunosuppressive agents can cause drug-induced pruritus as a side effect or alter skin barrier function.
4. Recommended Management Approach
Per textbook evidence:
| Step | Intervention |
|---|---|
| First-line | Non-sedating H1 antihistamine (cetirizine, fexofenadine, loratadine) — can increase up to 4× daily dose |
| Add-on | Montelukast 10 mg/day (already on this) + H2 blocker (famotidine/ranitidine) |
| Refractory chronic urticaria | Omalizumab (anti-IgE monoclonal antibody) — this is particularly relevant given elevated IgE |
| Aquagenic-specific | Capsaicin cream (desensitizes nerve fibers), topical barrier emollients before water exposure, UV-B phototherapy |
| Systemic disease workup | Check CBC (polycythemia vera), thyroid function, complement levels (C4, C2 for angioedema) |
— Harrison's Principles of Internal Medicine 22E; Andrews' Diseases of the Skin
5. Key Point: Omalizumab for IgE-Mediated + Refractory Urticaria
Since this patient has elevated IgE and symptoms persist despite montelukast and immunosuppression:
"For chronic urticaria that fails to respond to first-line options, a monoclonal anti-IgE antibody (omalizumab) is the next line of therapy." — Harrison's Principles of Internal Medicine 22E, p. 2852
Omalizumab directly targets free IgE, reduces mast cell surface IgE receptor expression, and has strong evidence for refractory chronic urticaria including inducible (water-triggered) forms.
Practical Advice for the Patient
- Apply a barrier (petroleum jelly/emollient) before water contact to reduce aquagenic trigger
- Take the antihistamine 30–60 minutes before bathing for preemptive control
- Do not suddenly stop immunotherapy — discuss with the allergist if symptoms worsen
- Discuss omalizumab with the treating physician as a targeted option given elevated IgE
- Rule out underlying systemic causes (blood count, thyroid, complement levels)
Note: This information is for clinical education purposes. The treating physician should guide any changes to the current immunotherapy or medication regimen.
Lab test
Asking for Preferences
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Based on authoritative sources, here is a complete guide to the lab tests relevant to this patient (IgE-mediated allergy + immunotherapy + montelukast + water-triggered itching):
Lab Tests for This Patient
🔬 Tier 1 — Essential / Baseline Tests
| Test | Purpose | What to Expect |
|---|---|---|
| CBC with differential | Detect eosinophilia (allergy), polycythemia vera (cause of aquagenic pruritus), anemia, infection | Eosinophils ↑ in allergy; RBC/Hct ↑ in polycythemia vera |
| Total serum IgE | Baseline atopic burden; guide omalizumab dosing | Elevated in atopic/allergic disease |
| Allergen-specific IgE (RAST/ImmunoCAP) | Identify exact allergen triggers | Positive to relevant allergens |
| CRP / ESR | Detect underlying inflammation or systemic disease | Often normal in simple urticaria |
| TSH (Thyroid) | Thyroid autoimmunity is associated with chronic urticaria | May be elevated or suppressed |
— Washington Manual of Medical Therapeutics; Harrison's Principles of Internal Medicine 22E
🔬 Tier 2 — Targeted / Important Tests
| Test | Purpose |
|---|---|
| Serum tryptase | Elevated in mastocytosis and anaphylaxis — important given mast cell involvement in IgE urticaria |
| Complement levels (C4, C1-INH) | Rule out hereditary angioedema (HAE) — especially if angioedema (swelling) is present alongside itching |
| Renal function (BMP/CMP) | Baseline monitoring, especially with immunosuppressive therapy |
| Liver function tests (LFTs) | Montelukast can rarely cause hepatotoxicity; immunosuppressants also require LFT monitoring |
| JAK2 V617F mutation / Hematocrit | Rule out polycythemia vera if aquagenic pruritus (water-triggered itching without wheals) is prominent |
"All patients with angioedema without urticaria should be screened with a C4 level... If the C4 level is reduced, a quantitative and functional C1 INH assay should be performed." — Washington Manual of Medical Therapeutics, p. 435
🔬 Tier 3 — Advanced / Specialist Tests
| Test | Purpose |
|---|---|
| Autologous serum skin test (ASST) | Detects autoantibodies against IgE receptor — confirms autoimmune urticaria |
| Anti-FcεRI & anti-IgE autoantibodies | Confirms autoimmune basis for chronic urticaria |
| Basophil activation test (BAT) | Measures basophil degranulation to confirm allergen sensitivity |
| Skin prick test / intradermal test | Confirms specific IgE-mediated allergies; used to guide immunotherapy |
🔬 Monitoring Tests During Immunotherapy + Immunosuppression
| Test | Frequency | Reason |
|---|---|---|
| CBC | Regularly (monthly or per protocol) | Monitor for bone marrow suppression from immunosuppressants |
| LFTs | Every 3–6 months | Hepatotoxicity from immunosuppressants and montelukast |
| Renal function | Every 3–6 months | Nephrotoxicity (e.g., cyclosporine) |
| Total IgE | Periodically | Track response to immunotherapy; guide omalizumab dosing |
Key Point on Aquagenic Pruritus (Water-Triggered Itching)
If itching specifically occurs with water contact, polycythemia vera must be ruled out:
- CBC → look for Hct >52% (men) or >48% (women), elevated RBC mass
- JAK2 V617F mutation → present in ~95% of polycythemia vera cases
- Serum erythropoietin → low in polycythemia vera
Summary Priority Order:
- CBC with differential
- Total + specific IgE
- TSH, CRP, CMP (renal + liver)
- C4 / C1-INH (if swelling present)
- Serum tryptase
- JAK2 mutation (if water-only itching without hives)
These results help the treating physician decide whether to escalate to omalizumab, adjust immunotherapy dosing, or investigate for an underlying systemic cause.
This is a shared conversation. Sign in to Orris to start your own chat.